Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

MDS Pharma Services adopts SAS Drug Development tool

MDS Pharma Services : 18 June, 2008  (Company News)
MDS Pharma Services has adopted the SAS Drug Development tool to provide a centralised, integrated system for managing, analysing, reporting and reviewing clinical research data.
SAS Drug Development technology is being implemented across MDS Pharma Services from the pre-clinical line of business through Phase IV to integrate worldwide work flows. It also speeds conversion of data sets into the format established by the Clinical Data Interchange Standards Consortium (CDISC) for electronic regulatory submissions.

'This powerful tool will significantly improve our internal operational efficiency and enhance our ability to provide quality, on-time service to clients at all phases of their drug development process,' said MDS Pharma Services president David Spaight. 'It allows clients to view their study data even as it is being updated, serves as a secure repository of legacy clinical trial data, and can convert that data into standard CDISC format for electronic submission to regulators as part of a New Drug Application.'

With the SAS Drug Development system, MDS Pharma Services can offer medium to large pharmaceutical industry clients the ability to combine historical clinical trial data from a variety of sources and studies, convert it to a common format and analyse it to identify Patient safety issues or new demographic groups with commercial potential. For biotech clients, this tool will enable the integration of all available trial datasets and their conversion into a unified data package for due diligence, subsequent licensing or joint venturing with a potential commercial development partner.

'Collaboration within the R and D process must include shared visibility to information,' said Jason Burke, worldwide director of Health and Life Sciences at SAS. 'The aggregation and analysis of standardised data across a compound's lifecycle establishes a foundation for improving pharmaceutical R and D, and organizations like MDS Pharma Services that can operationalise these improvements have a distinct competitive advantage.'

SAS Drug Development provides a centralized, integrated system for managing, analysing, reporting and reviewing clinical research information. The solution enables life sciences organizations to get products to market faster by more effectively assessing the safety and efficacy of research compounds. The solution also facilitates collaboration across trials, phases and therapeutic areas.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo